FDA official logo
GSRS logoPFDA official logo

VARZUTAMIG

UNII:MG3X2KS55Q
Type:INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:VARZUTAMIG
GSRS Full Record:

  • 3064817-31-5
  • Immunoglobulin, trispecific, anti-(human serum albumin) (human-Lama glama monoclonal JXA2198 single-domain VHH fragment) fusion protein with peptide linker (GGGGSGGGSGG) fusion protein with prodomain peptide (synthetic masking moiety and protease-cleavable moiety-containing) fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal JXA2438 single-chain variable fragment VH-(GGGGS)3-VL) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin G1 anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JXA6549 VH-CH1 fragment) disulfide with prodomain peptide (synthetic masking moiety and protease-cleavable moiety-containing) fusion protein with human-Mus musculus monoclonal JXA6549 κ-chain
  • Varzutamig
  • fused heavy chain VH-prodomain-scFvhl-VH-G1(CH1-h5) heavy chain (VH anti-ALB humanized, scFvhl anti-CDE3E chimeric and Homo sapiens, and VH anti-EGFR chimeric) (H) (1-653) [VH anti-ALB humanized (Homo sapiens IGHV3-23*04 (81.4%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.17] (26-33.51-58.97-113)) (1-124)-prodomain [9-mer tetraglycyl-seryl-triglycyl-seryl linker (125-133) -16-mer GGVYCGPEFDESVGCM mask (134-149) -8-mer tetraglycyl-seryl-triglycyl linker (150-157) -16-mer LSGRSDAGSPLGLAGS cleavable linker (158-173) -4-mer triglycyl-seryl linker (174-177)] (125-177) -scFvhl anti-CD3E chimeric (178-426) [VH Musmus/Homsap (Mus musculus IGHV10-1*04 (92.0%) -(IGHD) -IGHJ3*01 (86.7%)/Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ5*01 (100%), CDR-IMGT [8.10.16] (203-210.228-237.276-291)) (178-302) -15-mer tris(tetraglycyl-seryl) linker (303-317) -V-LAMBDA (Homo sapiens IGLV7-43*01 (85.1%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (343-351.369-371.408-416)) (318-426)] -5-mer tetraglycyl-seryl linker (427-431) -VH-G1(CH1-h) anti-EGFR chimeric (432-653)[VH (Mus musculus IGHV2-2*03 (93.8%) -(IGHD) -IGHJ3*01 (100%), CDR-IMGT [8.7.13] (457-464.482-488.527-539)) (432-550) -Homo sapiens IGHG1*01 (CH1-h5) (CH1 G1m17, CH1 K120(647) (551-648), hinge 1-5 (649-653)) (551-653)]], (653-256')-disulfide with fused light chain prodomain-L-kappa light chain anti-EGFR chimeric (L') (1'-256') [prodomain (16-mer GGPCRSHIDVAKPICV mask (1'-16') -7-mer tetraglycyl-seryl-diglycyl linker (17'-23') -16-mer LSGRSDAGSPLGLAGS cleavable linker (24'-39') -3-mer diglycyl-seryl linker (40'-42')) (1'-42') -V-KAPPA (Mus musculus IGKV5-48*01 (95.8%) -IGKJ5*01 (100%), CDR-IMGT [6.3.9] (69'-74'.92'-94'.131'-139')) (43'-149') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (195'), V101 (233')) (150'-256')], produced in a cell line of Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
  • immunoglobulin VH-prodomain-scFvhl-VH-G1(CH1-h5)_prodomain-L-kappa, anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized, Homo sapiens and chimeric monoclonal antibody, trispecific, trivalent (varzutamig)
  • varzutamig [INN]



UNII - MG3X2KS55Q | UNII Search Service